Skip to main content
Equibles

ADAPY · Adaptimmune Therapeutics PLC · Webcasts, Transcripts & Audio

Track ADAPY — free

Use ADAPY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADAPY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 +0.00 (+11.30%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2025

Substantial doubt about the company's ability to continue as a going concern.

“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”
View the 10-Q filed Aug 13, 2025
Market Cap
$44.53M
Shares
1.59B
Volume · Oct 20 80.26K Avg daily vol (3M) 144.54K

Adaptimmune Therapeutics PLC Webcasts

Earnings calls, investor updates, investor days and conferences for Adaptimmune Therapeutics PLC (ADAPY), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY25 · Q1
2025-05-13
Adaptimmune Therapeutics PLC (ADAPY) Q1 2025 Earnings Call
Revenue
$7.29M
▲ 28.3% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Adaptimmune Therapeutics PLC (ADAPY) Q4 2024 Earnings Call
Revenue
$3.22M*
▲ 1294.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Adaptimmune Therapeutics PLC (ADAPY) Q3 2024 Earnings Call
Revenue
$40.90M
▲ 458.8% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Adaptimmune Therapeutics PLC (ADAPY) Q2 2024 Earnings Call
Revenue
$128.23M
▲ 2399.6% YoY
Diluted EPS
$0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Adaptimmune Therapeutics PLC (ADAPY) Q1 2024 Earnings Call
Revenue
$5.68M
▼ 88.1% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Adaptimmune Therapeutics PLC (ADAPY) Q4 2023 Earnings Call
Revenue
$231,000*
▼ 97.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Adaptimmune Therapeutics PLC (ADAPY) Q3 2023 Earnings Call
Revenue
$7.32M
▲ 4.5% YoY
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Adaptimmune Therapeutics PLC (ADAPY) Q2 2023 Earnings Call
Revenue
$5.13M
▼ 7.4% YoY
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Adaptimmune Therapeutics PLC (ADAPY) Q1 2023 Earnings Call
Revenue
$47.60M
▲ 1231.5% YoY
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Adaptimmune Therapeutics PLC (ADAPY) Q4 2022 Earnings Call
Revenue
$11.03M*
▲ 678.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Adaptimmune Therapeutics PLC (ADAPY) Q3 2022 Earnings Call
Revenue
$7.01M
▲ 482.5% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Adaptimmune Therapeutics PLC (ADAPY) Q2 2022 Earnings Call
Revenue
$5.54M
▲ 78.9% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Adaptimmune Therapeutics PLC (ADAPY) Q1 2022 Earnings Call
Revenue
$3.58M
▲ 723.7% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
Adaptimmune Therapeutics PLC (ADAPY) Q4 2021 Earnings Call
Revenue
$1.42M*
▼ 5.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Adaptimmune Therapeutics PLC (ADAPY) Q3 2021 Earnings Call
Revenue
$1.20M
▲ 0.8% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Adaptimmune Therapeutics PLC (ADAPY) Q2 2021 Earnings Call
Revenue
$3.10M
▲ 516.5% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Adaptimmune Therapeutics PLC (ADAPY) Q1 2021 Earnings Call
Revenue
$434,000
▼ 43% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Adaptimmune Therapeutics PLC (ADAPY) Q4 2020 Earnings Call
Revenue
$1.50M*
▲ 106.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Adaptimmune Therapeutics PLC (ADAPY) Q3 2020 Earnings Call
Revenue
$1.19M
▲ 403.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Adaptimmune Therapeutics PLC (ADAPY) Q2 2020 Earnings Call
Revenue
$502,000
▲ 219.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-14
Adaptimmune Therapeutics PLC (ADAPY) Q1 2020 Earnings Call
Revenue
$761,000
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Adaptimmune Therapeutics PLC (ADAPY) Q4 2019 Earnings Call
Revenue
$728,000*
▼ 50.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–22 of 22 webcasts
Key facts CIK 1621227 CUSIP 00653A107 Visit website Investor relations